Author Archives: admin


Stem Cell Clinic > Articles by: admin

Living to 100 with Anti-Aging and Rejuvenation Stem Cells Therapy

By Stem Cell Treatment

The state of the art Laboratory and clinic at World Stem Cells Clinic announces its latest in Stem Cell Treatments and procedures to rejuvenate the face, body, organs and increase the feeling of well being.

Lutz, Florida (PRWEB) February 07, 2013

The Stem Cell Treatment at World Stem Cells Clinic takes 5 days to complete as the treatments are comprehensive and designed to maximize the benefits and safety a patient derive from the process.

World Stem Cells, LLC worldstemcells.com will provide patient management service assisting the patient on their flight, hotel, provide transportation to and from the airport, transportation to and from your hotel to World Stem Cells Clinic, provide 24/7 communication and be the patients ombudsmen.

FACTS ABOUT AGING

The science shows each minute, our body is dying, this is a fact. Each minute that passes by our body has lost 300,000,000 cells. That means the cells that die in our body equals the population of the United States, each and every single minute. As we age less and less of those cells are replace and we slowly decay. Doctors have see people over a 100 that if cut nothing happens as there are no cells to close the wound.

Thus Aging is a result of progressive depletion of stem cells, so the introduction of new stem cells and adjunctive treatments has the potential of slowing down or reversing this process. Stem cells possess a unique anti-aging effect by regenerating and repairing organs, improving immune function, repair damaged by stress, and various toxins we are exposed to in our daily life.

Stem Cells often thought of as futuristic, controversial and unknown, are now providing the latest anti-Aging, rejuvenation and beauty secret.

THE SIGNS OF AGING

The signs of aging generally start at 40, earlier for those who have burned the candle at both ends , smokers, have been under stress or in contact with toxic sustenances and generally later for those who have had less stress, non smokers, exercised and eat properly but in the end we all will age. Some of the signs of aging are:

Read the original:
Living to 100 with Anti-Aging and Rejuvenation Stem Cells Therapy

Scientists Say 3D Printing Can Create Stem Cells – Video – Stem …

By Stell Cell Research

Feb 07

Scientists Say 3D Printing Can Create Stem Cells Scientists say that 3D printing can create stem cells. Stem cells can now be produced using a form of 3D printing technology. (1,1,1) Developed by scientists from Heriot Watt University in Edinburgh, Scotland(1,8,1) the 3D printing technology is capable of making embryonic stem cells that can differentiate into any other kind of cell in the human body. (2,9,1) 3D printing has been used in various different industries, (2,1,1) but this is the first time that a human embryonic stem cell has been created this way. According to BBC News, Jason King, business development manager of stem cell biotech company Roslin Cellab, which took part in the research, (1,15,1) said: This is a scientific development which webelieve will have immensely valuable long-term implications for reliable, animal-free, drug testing, and, in the longer term, to provide organs for transplant on demand, without the need for donation and without the problems of immune suppression and potential organ rejection. The 3D printers make dots containing up to five stem cells from cultures that are floating in a bio ink. The printing process did not appear to damage the cells as researchers found that 99 percent of the cells remained usable. What do you think? Is this kind of stem cell technology development a step in the right direction?

By: GeoBeatsNews

See the article here: Scientists Say 3D Printing Can Create Stem Cells Video

Link:
Scientists Say 3D Printing Can Create Stem Cells – Video – Stem ...

Monell scientists identify taste stem cells on the tongue – Stem Cell …

By Stell Cell Research

Thediscovery of until now elusive taste stem cells on the tongue will help researchers and industry better understand the complexities of human taste, say researchers.

The breakthrough, byresearchers at the Monell Chemical Sciences Center, USA, will help to develop new techniques to grow and manipulate fully functional taste cells for use in research and clinical treatments, say thescientists behind the finding.

Writing in the journal Stem Cells,the Monell team explains that for decades taste scientists have attempted to identify the stem or progenitor cells that spawn the different taste receptor cells. This elusive challenge also sought to establish whether one, or several, progenitors were involved, and where they were located, they said.

Led by senior author Dr Peihua Jiang, the research team said that the identification of the location and certain genetic characteristics of taste stem cells on the tongue will kick-start research that better understands the make-up of human taste, and could someday help treat clinical taste dysfunctions.

This is just the tip of the iceberg, said Jiang. Identification of these cells opens up a whole new area for studying taste cell renewal, and contributes to stem cell biology in general.

Cancer patients who have taste loss following radiation to the head and neck and elderly individuals with diminished taste function are just two populations who could benefit from the ability to activate adult taste stem cells, explained Dr Robert Margolskee, who also worked on the study.

Tasty findings

The team explained that taste cells are located in clusters called taste buds, which in turn are found in papillae, the raised bumps visible on the tongues surface. In these structures, there are two types of taste cells that contain the chemical receptors that initiate perception of sweet, bitter, umami, salty, and sour taste qualities while a third type appears to serve as a supporting cell.

A remarkable characteristic of these sensory cells is that they regularly regenerate, said the researchers. All three taste cell types undergo frequent turnover, with an average lifespan of 10-16 days. As such, new taste cells must constantly be regenerated to replace cells that have died.

Read more from the original source: Monell scientists identify taste stem cells on the tongue

The rest is here:
Monell scientists identify taste stem cells on the tongue – Stem Cell ...

Stem-cell doctor Grekos should lose license, pay heavy fines, costs, state recommends

By Stem Cell Treatment

Photo by Allie Garza

Zannos Grekos

Bonita Springs cardiologist Zannos Grekos should lose his license because he committed medical malpractice in performing an unscientific stem cell procedure on a patient who died, according to new case filings.

State Department of Health attorneys also recommend that a judge fine Grekos the maximum $40,000 and order him to pay expenses to investigate and prosecute him, according to the states recommended order to the judge.

The state costs to date are $200,222, according to Department of Health spokeswoman Ashley Carr.

The case involves Grekos' unorthodox stem-cell therapy on 69-year-old Domenica Fitzgerald in 2010, who suffered a stroke and was taken off life support. She died April 4, 2010.

John Fitzgerald, the victim's husband, pointed out Wednesday that the three-year anniversary of his wife's death is approaching.

"I'm worn out," he said. "I want some closure. My family wants closure."

Still, he said the state's two prosecutors have worked hard, and he had been told that $200,000 had been spent so far on the case.

"I know the system is slow," he said. "It seems to be working."

More:
Stem-cell doctor Grekos should lose license, pay heavy fines, costs, state recommends

Stem cell discovery identifies potential obesity treatment

By Stem Cell Treatment

Nutrition and Fitness Health Home>>Nutrition and Fitness>>Health news Written by: QMI Agency Feb. 6, 2013 (SHUTTERSTOCK)

Scientists at the Ottawa Hospital Research Institute say they have discovered a trigger that turns muscle stem cells into brown fat, a form of good fat that could play a critical role in the fight against obesity.

"This discovery significantly advances our ability to harness this good fat in the battle against bad fat and all the associated health risks that come with being overweight and obese," Dr. Michael Rudnicki, a senior scientist at the Institute, said in a statement Tuesday.

The research team say mice that were injected with an agent to reduce a gene regulator called miR-133 produced more brown fat, were protected from obesity and had an improved ability to process glucose.

Did you find what you were looking for on our website? Please let us know.

See the article here:
Stem cell discovery identifies potential obesity treatment

3D printing with stem cells could lead to printable organs – Stem …

By Stell Cell Research

Feb 06

A potentially breakthrough 3D-printing process using human stem cells could be the precursor to printing organs from a patients own cells.

3D-printed stem cells act like ink.

Some day in the future, when you need a kidney transplant, you may get a 3D-printed organ created just for you. If scientists are able to achieve that milestone, they may look back fondly at a breakthrough printing process pioneered by researchers at Heriot-Watt University in Scotland in collaboration with Roslin Cellab, a stem cell technology company.

The printer creates 3D spheroids using delicate embryonic cell cultures floating in a bio ink medium. They end up looking like little bubbles. Each droplet can contain as few as five stem cells. Basically, this comes down to the printer ink being stem cells rather than plastic or another material.

Dr. Will Shu is part of the research team working on the project. In the longer term, we envisage the technology being further developed to create viable 3D organs for medical implantation from a patients own cells, eliminating the need for organ donation, immune suppression, and the problem of transplant rejection, Shu said in a release from Heriot-Watt.

Perhaps most importantly, the stem cells survived the printing process and remained viable. Shu says this is the first time human embryonic stem cells have been 3D printed. Printing out organs may be far down the line, but its just one potential application. The method could also be used to print out human tissue for drug testing.

The research results have just been published in Biofabrication under the title Development of a valve-based cell printer for the formation of human embryonic stem cell spheroid aggregates.

While things like 3D-printed Mobius bacon strips and crazy pointy shoes are a lot of fun, its applications like this that could really turn 3D printing into a world changer.

(Via PopSci)

See the article here:
3D printing with stem cells could lead to printable organs – Stem ...

Stem cells is no hype but it is a better hope: Experts – Stem Cell Cafe

By Stell Cell Research

One day 2 of Bangalore India Bio (BIB) Indias premier Biotech Show organised by the department of Information Technology, Bio-Technology and Science & Technology, Government of Karnataka and the Vision Group on Biotechnology, featured another TRACK ON REGENERATIVE MEDICINE, the topic was THE PROMISES AND CHALLENGES OF REGENERATIVE MEDICINE. The session was Chaired by B.N. Manohar Chief Executive Officer, Stempeutics Research Pvt. Ltd. and the Speakers were Prof. Ravi Bellamkonda Associate Vice President for Research, Carol Ann and David D. Flanagan Chair in Biomedical Engineering & GCC Distinguished Scholar, Georgia Institute of Technology, USA, Dr. N.K. Venkataramana Director of Advanced Neuro-Science Institute and Vice-Chairman of BGS-Global Hospitals and Dr. Suresh Babu Application Scientist, Life Science Centre (R&D), Agilent Technologies.

Opening the session B.N. Manohar, said, Today regenerative medicine, stem cells, neurology have tremendous potential. Bio Pharma can change the present US$5bn to US$100billion by 2025. Globally US$150bn revenue is made by Biotechnology industries in which 15% is from Pharma industries. In which India contributes 10% to pharma revenue. Stem cells will become a major benchmark for medical treatment. They can be utilized in many ways, which will be shared by the Panel.

Prof. Ravi Bellamkonda, said, the concept of damaged cells to regenerate the cells in the nerve gap, the polymer drug for the cell therapy to grow organwhich is to be viable but need investments. When the nerve gaps are more than 10mm they dont heal fast on their own, Surgeons use pseudo nerve for nervegrafting. Nerve grafting has many disadvantages like second surgery, rate multiple grafting etc 40% success rate, to overcome this is designing the ideal bridge inthe nerve gaps. We are working in our lab to design a pseudo nerve which has genetic approach which has the capacity for bridging for auto grafting and alsodeveloping a gel. This was developed directly in the tissues but it did not work so we tried to work with the embryonic cells (rat), fiber cells with polymer whichallows the gel formation which allows the nerve growth. The Schwann cells which migrated to the glial cells for the growth of nerve cells. This takes nearly 10years for the treatment so trying to concentrate for the short term a treatment which promotes the nerve bridge. We worked on Peripheral nerve submerges withmacrophage which responds to the M2 phenotype for the auto grafting, the Schwann cells migrates quickly regenerating the cells, the study is still under process.We will be able to provide more jobs as we expand.

Dr. N. K. Venkataramana, in his talk said, Started with advancement in medicine from past 3decades and the UN met medical needs in neurological disorders alone we have more than 15 million people adding on every year and their accounts to 300 million which is a huge burden. For this burden stem cells was a boon in the field. We thought that the fundamental property and its cell repairing capacity can be exploited by the scientists and a way to meet the medical needs. Our main goal is to inject the stem cells into the body, so the natural power of regeneration can be enhanced and supported. All stem cells are not equal, majority of us use adult stem cells, embryonic stem cells for the research. Use of Mesenchymal stem cells a multipotent, hypo neurogenic in large scale production is possible. Bone marrow transplantation was known because of stem cells, till then we never saw. With the advancement we can distinguish the cells and utilize for the purpose. In past 30 years I have never seen a recovery of spinal cord injury but now the stem cells giving hope that even in the case of head injury, Parkinsons disease recovery is possible. Understanding the mechanism of action is difficult, follows few postulates they are activation of stem cells, regeneration of cells, Immunomodulation, secretion of growth factors. Mesenchymal cells are Immunomodulatory, secrete many bio active molecules, which has anti apocratic effect, Immunomodulatory, angiogenesis, antifibrotic effect, these can be exploited in many ways for the medical purpose. Different sources of stem cells give different genetic expressions and can be used for different purpose. Concluding with all this data available today, stem cells is no longer a hype but it is a better hope.

Dr. Suresh Babu, an Application Scientist, extensively with proteins and has presented 25 papers till date said, Proteins can undergo various kinds ofmodifications. This is the reason for the different characterizations of proteins. Thus, for different characterizations, new technology is required. The AgilentToolbox for Biologic Characterization is a product of Agilent Technologies. It is used for Intact mAb (Monoclonal Antibodies) Analysis, i.e. to analyze inactiveantibodies. A new chip known as the HPLC Chip is used, which is used in 4 steps Setup, Insert, Click (on the software) and Spray the sample. The chip hasbeen elemental in deconvulating the MS Spectrum of intact mAbs. To do this, PNGase F treatment is done. The Glycons show a missing peak. To show aclear spectrum, the number of antibodies are reduced. This same process can be done on Fc fragments as well. It has practical significance as well, because only1 nanogram of the sample is required, as opposed to over 200 nanograms in conventional methods.

Another application this technology is used in is Peptide Mapping. The peptides are subjected to the data. 94% Heavy Chains and 84% Light Chains are reported. Peptide mapping can also be done by using U.V rays.

Another new detector has been developed to increase sensitivity. About 10% increase has been reported. Size Exclusion Chromatography(SEC) is performedto show the aggregation of mAb. All the systems devised by Agilent technologies are metal and Iron free so that they do not react with the biomolecules. HeatStress has also been done to degrade the antibodies. Aggregates of the protein molecules have been by pH Stress. A linearity curve was plotted whichshowed the concentration of the sample to be 12.5-2000 micrograms per milliliter. For charged varients, Ion Exchange Chromatography(IEC) is widelyused.he added.

More: Stem cells is no hype but it is a better hope: Experts

The rest is here:
Stem cells is no hype but it is a better hope: Experts – Stem Cell Cafe

Cutting-Edge Medical And Stem Cell Technology Available In The Philippines But DoH cites concerns

By Stem Cell Treatment

Department of Health Undersecretary Dr. Teodoro Herbosa recently urged the public seeking treatment using stem cell technology to only undergo procedure initiated by reputable hospitals in the country.

The highly advanced procedure of using stem cell technology has recently gained popularity due to success claims of scientists here and abroad. However, due to the increasing demand for this technology, USEC Herbosa expressed concern that some individuals needing treatment might end-up in bogus clinics usually offering lower fees. "Just to ensure safety, it will be best for patients to seek treatment only among reputable hospitals," Usec. Herbosa stated in an interview.

Incidentally, a leading global Filipino scientist in the field of genetics and microbiology stated that the Philippines is now one of the leading countries in the world, even a step ahead of Germany, in the field of health science. Presidential Awardee Dr. Samuel D. Bernal, a Filipino-American regenerative medicine expert, medical oncologist, molecular biologist, chemist and a lawyer, calls on Filipinos here and abroad to patronize the technology we have here in the country.

"Very few know about it, but we can already actually culture or clone a human heart in the Philippines," claimed by Dr. Bernal in a recent lecture he delivered recently at UST College of Medicine CME Auditorium before hundreds of University of Sto. Tomas scientists, professors, medical doctors and students.

During the lecture event, dubbed, "Future of Molecular Medicine," Dr. Bernal discussed the beauty, art and importance of molecular medicine in addressing modern-day health problems such as cancer.

Dr. Bernal also talked about the state-of-the-art laboratory he has set up at the Medical City in Ortigas. "We already have the technology, the facility, and numerous experts trained abroad to do the procedures we thought can be accessible only by going to other advanced countries. Our efforts generate jobs for medical experts here, tempted to leave the country to work abroad. We are proud to say patients from other countries choose us over other facilities from other countries because not only are we at par with their services but we are also much affordable compared to treatments done in Germany or Singapore," Dr. Bernal asserts.

The recipient of Presidential Awards for Filipino Individuals and Organizations Overseas conferred by President Benigno S. Aquino III and the Commission on Filipino Overseas (CFO), Dr. Bernal is an accomplished medical expert who finished his fellowship training in Cancer medicine and Cell Biology at Harvard Medical School not to mention his internship and residency in Internal Medicine at the Johns Hopkins Hospital. He returned to the country to put-up a facility on regenerative medicine, molecular medicine laboratory for tumor profiling for drug resistance and sensitivity, and a comprehensive stem cell bank which collects babies' umbilical cords for the family's future use in treatment using stem cell technology.

Read more:
Cutting-Edge Medical And Stem Cell Technology Available In The Philippines But DoH cites concerns

First Patient Begins Treatment in BrainStorm’s Phase IIa Trial for ALS

By Stem Cell Treatment

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Companys Phase IIa dose-escalating clinical trial for ALS. The trial, which will evaluate the safety and preliminary efficacy of BrainStorms NurOwn stem cell therapy candidate, is being conducted at the Hadassah Medical Center in Jerusalem.

In the Phase IIa trial, three groups of four patients will receive combined intramuscular and intrathecal administration of NurOwn cells, in increasing doses. The first cohort of four patients is expected to complete treatment by the end of April 2013. The trial participants will be monitored for three to six months following transplantation.

We are excited to be treating the first patient in this trial, which will build on the excellent safety profile and encouraging positive results from our Phase I/II study, commented Alon Natanson, BrainStorms CEO.

This trial will provide valuable data not only on the safety of NurOwn in ALS patients, but also on the ability of different dosing levels to provide clinical benefit, added Prof. Dani Offen, the Companys Chief Scientific Advisor.

Israels Ministry of Health recently approved BrainStorms acceleration to a Phase IIa trial following the positive safety evaluation of the first 12 patients in the companys recent Phase I/II trial at Hadassah. A description of the trial can be found at: http://www.clinicaltrials.gov/ct2/show/NCT01777646?term=NCT01777646&rank=1.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as may, should, would, could, will, expect, likely, believe, plan, estimate, predict, potential, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorms forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or managements beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Excerpt from:
First Patient Begins Treatment in BrainStorm’s Phase IIa Trial for ALS

International Stem Cell Corporation Announces Positive Results From In Vivo Animal Study of Parkinson's Disease

By Stem Cell Treatment

CARLSBAD, CA--(Marketwire - Feb 4, 2013) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company, today announced positive 12-week results from its pre-clinical in vivo Parkinson's disease study. The primary goal of this behavioral study was to demonstrate the therapeutic benefits of neuronal cells derived from human parthenogenetic stem cell (hpSC) line in a rat model of Parkinson's disease (PD).

Parkinson's disease is a common neurodegenerative disorder caused by a progressive degeneration of dopamine-producing neurons resulting in gradual dysfunction of the motor system and can eventually lead to death. Pharmacological treatments are useful in the relatively early stage of the disease, but the continuous use of pro-dopaminergic medication eventually becomes ineffective and can cause some of the motor symptoms to worsen.

Our proprietary technology is based on a homogeneous population of neuronal cells (NCs) derived from homozygous hpSCs through a scalable and efficient method, developed by ISCO's R&D team. These parthenogenetically-derived NCs are cryopreservable and can become neurons once they are implanted into the brain. As such, they hold significant therapeutic potential not only because they can differentiate into dopamine-producing neurons, but also because these cells deliver trophic factors that may be able to provide a level of protection to existing neurons affected by the disease.

The animal model used in this study is the 6-OHDA lesioned rat, a well-established and validated model of PD which has been used extensively in the development and testing of drugs for the treatment of PD. The pharmacological induction of rotational behavior in rats is widely used to assess the effects of lesions and potential of cell therapy to effectively replace the dopaminergic system in the rat brain and thus serves as a model of PD. The experimental rats with unilateral dopamine (6-OHDA) lesions survived the inoculation of cells into the brain and signs of improvement in rotational behavior of these animals were clearly observed. Correlational analysis of rotation intensity demonstrated a difference between the drug effects in the control group vs. experimental (transplanted) group of animals. These interim results demonstrate that a single injection of hpSC-derived neuronal cells into the striatum of rats with induced PD symptoms can lead to a significant slowdown in the progression of the disease.

Dr. Ruslan Semechkin, Vice President - head of R&D, comments: "This is a very important result for our pre-clinical Parkinson's program. The initial in vivo results are very encouraging and show the therapeutic promise of hpSC-derived neuronal cells in the treatment of individuals with Parkinson's disease. Results from this behavioral study will be presented and discussed together with the results of non-human primate study before the end of the first quarter of 2013"

About International Stem Cell CorporationInternational Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Safe harbor statement Statements pertaining to anticipated developments, the potential use of technologies to develop therapeutic products and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" or "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Visit link:
International Stem Cell Corporation Announces Positive Results From In Vivo Animal Study of Parkinson's Disease

→←